|
BRPI0417302A
(pt)
|
2003-12-05 |
2007-03-06 |
Compound Therapeutics Inc |
inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
|
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
|
WO2009102421A2
(en)
|
2008-02-14 |
2009-08-20 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
|
EP2291399B1
(en)
|
2008-05-22 |
2014-06-25 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
|
|
JP2013523179A
(ja)
*
|
2010-04-13 |
2013-06-17 |
メディミューン，エルエルシー |
フィブロネクチンタイプｉｉｉドメインに基づく多量体足場
|
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
|
US9562089B2
(en)
|
2010-05-26 |
2017-02-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
|
DK2697257T3
(en)
|
2011-04-13 |
2017-01-30 |
Bristol Myers Squibb Co |
FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
|
|
EP3318880B1
(en)
|
2011-05-17 |
2020-12-16 |
Bristol-Myers Squibb Company |
Improved methods for the selection of binding proteins
|
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
|
ES2819075T3
(es)
|
2011-10-11 |
2021-04-14 |
Viela Bio Inc |
Matrices de soporte derivadas de TN3 específicas para CD40L y sus métodos de empleo
|
|
US9522951B2
(en)
|
2011-10-31 |
2016-12-20 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
|
CA2854806A1
(en)
|
2011-11-07 |
2013-05-16 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
|
JP6284482B2
(ja)
|
2011-11-08 |
2018-02-28 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
インターロイキン４およびインターロイキンを含む融合タンパク質
|
|
TWI694085B
(zh)
|
2012-09-13 |
2020-05-21 |
美商必治妥美雅史谷比公司 |
結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
|
|
US9695228B2
(en)
*
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
WO2014120891A2
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
|
EP2953968B1
(en)
|
2013-02-06 |
2018-07-25 |
Bristol-Myers Squibb Company |
Fibronectin type iii domain proteins with enhanced solubility
|
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
ES2645634T3
(es)
|
2013-02-12 |
2017-12-07 |
Bristol-Myers Squibb Company |
Métodos de replegado de proteínas a elevado pH
|
|
WO2014165093A2
(en)
|
2013-03-13 |
2014-10-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
|
SI2970473T1
(sl)
|
2013-03-14 |
2017-10-30 |
Bristol-Myers Squibb Company |
Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
|
|
US10392611B2
(en)
|
2013-05-30 |
2019-08-27 |
Duke University |
Polymer conjugates having reduced antigenicity and methods of using the same
|
|
US10364451B2
(en)
|
2013-05-30 |
2019-07-30 |
Duke University |
Polymer conjugates having reduced antigenicity and methods of using the same
|
|
CN105899226B
(zh)
*
|
2013-10-14 |
2020-05-12 |
詹森生物科技公司 |
半胱氨酸工程化iii型纤连蛋白域结合分子
|
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
|
JP6591437B2
(ja)
|
2014-03-20 |
2019-10-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン
|
|
MX371403B
(es)
|
2014-03-20 |
2020-01-29 |
Bristol Myers Squibb Co |
Moleculas de andamiaje a base de fibronectina estabilizada.
|
|
WO2015148269A2
(en)
*
|
2014-03-24 |
2015-10-01 |
Medimmune, Llc |
Stabilized tnfn3 scaffold proteins
|
|
NO2776305T3
(US20090208454A1-20090820-C00047.png)
|
2014-04-23 |
2018-01-27 |
|
|
|
CN114057857A
(zh)
*
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
|
BR112017006602A2
(pt)
|
2014-10-01 |
2017-12-19 |
Medimmune Llc |
método de conjugação de um polipeptídeo
|
|
WO2016086036A2
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
|
AU2016228806B2
(en)
|
2015-03-12 |
2020-10-22 |
Medimmune, Llc |
Method of purifying albumin-fusion proteins
|
|
US10385115B2
(en)
|
2015-03-26 |
2019-08-20 |
Duke University |
Fibronectin type III domain-based fusion proteins
|
|
KR20180002782A
(ko)
|
2015-05-06 |
2018-01-08 |
얀센 바이오테크 인코포레이티드 |
전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도
|
|
BR112018002342A2
(pt)
|
2015-08-04 |
2018-12-11 |
Univ Duke |
polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
|
|
US11124791B2
(en)
|
2015-09-14 |
2021-09-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Generating recombinant affinity reagents with arrayed targets
|
|
ES2967078T3
(es)
|
2015-09-23 |
2024-04-25 |
Bristol Myers Squibb Co |
Dominios de fibronectina de tipo III de unión a seroalbúmina con velocidad de disociación rápida
|
|
CN108884147B
(zh)
*
|
2015-09-23 |
2024-02-27 |
百时美施贵宝公司 |
结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
|
|
WO2017069627A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Universiteit Twente |
Integrin binding peptides and uses thereof
|
|
EA038551B1
(ru)
|
2015-12-17 |
2021-09-14 |
Дзе Джонс Хопкинс Юниверсити |
Способ лечения или профилактики системного склероза
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
WO2017177148A1
(en)
|
2016-04-07 |
2017-10-12 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
|
CN105802970A
(zh)
*
|
2016-05-30 |
2016-07-27 |
东北师范大学 |
靶向沉默Gβ1的shRNA
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
US11467156B2
(en)
|
2016-06-01 |
2022-10-11 |
Duke University |
Nonfouling biosensors
|
|
AU2017281083B2
(en)
|
2016-06-21 |
2022-01-27 |
Janssen Biotech, Inc. |
Cysteine engineered fibronectin type III domain binding molecules
|
|
RU2019110848A
(ru)
|
2016-09-14 |
2020-10-15 |
Дьюк Юниверсити |
Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
|
|
KR20190064600A
(ko)
|
2016-09-23 |
2019-06-10 |
듀크 유니버시티 |
Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
|
|
US10597438B2
(en)
|
2016-12-14 |
2020-03-24 |
Janssen Biotech, Inc. |
PD-L1 binding fibronectin type III domains
|
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
JP7104703B2
(ja)
|
2016-12-14 |
2022-07-21 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
|
|
WO2018132732A1
(en)
|
2017-01-12 |
2018-07-19 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
US10787499B2
(en)
*
|
2017-02-13 |
2020-09-29 |
Regents Of The University Of Minnesota |
EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
|
|
US11554097B2
(en)
|
2017-05-15 |
2023-01-17 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
EP3658168A4
(en)
|
2017-06-30 |
2021-07-14 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
|
|
US11491206B1
(en)
|
2018-02-13 |
2022-11-08 |
Duke University |
Compositions and methods for the treatment of trail-resistant cancer
|
|
US11680091B2
(en)
|
2018-02-23 |
2023-06-20 |
The University Of Chicago |
Methods and composition involving thermophilic fibronectin type III (FN3) monobodies
|
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
|
CN110724198B
(zh)
*
|
2018-07-17 |
2023-05-26 |
上海一宸医药科技有限公司 |
长效纤连蛋白iii型结构域融合蛋白
|
|
EP3829622A4
(en)
|
2018-08-02 |
2022-05-11 |
Duke University |
DUAL AGONIST FUSION PROTEINS
|
|
US11986536B2
(en)
|
2019-03-23 |
2024-05-21 |
Ablevia Biotech Gmbh |
Compound for the sequestration of undesirable antibodies in a patient
|
|
EP3715376A1
(en)
|
2019-03-23 |
2020-09-30 |
Ablevia biotech GmbH |
Compound for the prevention or treatment of myasthenia gravis
|
|
EP3715374A1
(en)
|
2019-03-23 |
2020-09-30 |
Ablevia biotech GmbH |
Compound for the sequestration of undesirable antibodies in a patient
|
|
EP3955955A1
(en)
|
2019-04-19 |
2022-02-23 |
Synerkine Pharma B.V. |
A fusion protein comprising il13
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
WO2020236795A2
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
CN114127304A
(zh)
|
2019-07-15 |
2022-03-01 |
免疫医疗有限公司 |
用于蛋白二聚化的三部分型系统和使用方法
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
US11628222B2
(en)
|
2019-10-14 |
2023-04-18 |
Aro Biotherapeutics Company |
CD71 binding fibronectin type III domains
|
|
CN111217903B
(zh)
*
|
2020-02-25 |
2022-11-15 |
芜湖天明生物技术有限公司 |
一种重组人纤连蛋白ⅲ1-c及其制备方法和应用
|
|
EP4110407A1
(en)
|
2020-02-28 |
2023-01-04 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
CN111944204B
(zh)
*
|
2020-07-24 |
2022-03-08 |
南京理工大学 |
一种Fe3O4磁性细菌纤维素及其制备方法
|
|
US20230381334A1
(en)
|
2020-09-23 |
2023-11-30 |
Ablevia Biotech Gmbh |
Compound for the sequestration of undesirable antibodies in a patient
|
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
|
|
BR112023005257A2
(pt)
|
2020-09-23 |
2023-04-25 |
Ablevia Biotech Gmbh |
Composto para a prevenção ou tratamento de condições mediadas por autoanticorpos
|
|
AU2021347582A1
(en)
|
2020-09-23 |
2023-05-18 |
Ablevia Biotech Gmbh |
Compound for increasing the efficacy of factor viii replacement therapy
|
|
KR20230074775A
(ko)
|
2020-09-23 |
2023-05-31 |
아블레비아 바이오테크 게엠베하 |
바이러스 벡터의 효능 증가를 위한 화합물
|
|
CN116710143A
(zh)
|
2020-09-24 |
2023-09-05 |
艾柏力维亚生技有限公司 |
用于预防或治疗重症肌无力的化合物
|
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
WO2023180502A1
(en)
|
2022-03-24 |
2023-09-28 |
Ablevia Biotech Gmbh |
Compound for increasing efficacy of oncolytic viruses
|
|
KR102459313B1
(ko)
*
|
2022-04-11 |
2022-10-26 |
주식회사 대영방재산업 |
내구성이 개선된 소방용 수격 흡수기
|
